Real-world analysis shows venetoclax and hypomethylating agent treatment impacts mortality in AML patients, suggesting better patient selection is needed.
Key Points
Complete remission rates were 54% among newly diagnosed acute myeloid leukemia patients treated with venetoclax.
Treatment led to a median survival of 11.1 months across 82 acute myeloid leukemia patients in real-world settings.
Next-generation sequencing was not performed in 42% of patients, impacting prognostic classification and outcomes.
Older patients (≥75 years) experienced significantly shorter survival compared to younger counterparts (13.3 vs. 6.2 months).